RU2386639C2 - Связывающие молекулы, обладающие терапевтической активностью - Google Patents

Связывающие молекулы, обладающие терапевтической активностью Download PDF

Info

Publication number
RU2386639C2
RU2386639C2 RU2006112598/13A RU2006112598A RU2386639C2 RU 2386639 C2 RU2386639 C2 RU 2386639C2 RU 2006112598/13 A RU2006112598/13 A RU 2006112598/13A RU 2006112598 A RU2006112598 A RU 2006112598A RU 2386639 C2 RU2386639 C2 RU 2386639C2
Authority
RU
Russia
Prior art keywords
seq
polypeptide
sequence
antibody
cd45ro
Prior art date
Application number
RU2006112598/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006112598A (ru
Inventor
Франк КОЛЬБИНГЕР (DE)
Франк Кольбингер
Хосе М. КАРБАЛЛИДО-ЭРЕРРА (AT)
Хосе М. КАРБАЛЛИДО-ЭРЕРРА
Андраш АСОДИ (AT)
Андраш АСОДИ
Хосе У. САЛДАНА (GB)
Хосе У. САЛДАНА
Брюс М. ХОЛЛ (AU)
Брюс М. ХОЛЛ
Сильвия ГРЕГОРИ (IT)
Сильвия ГРЕГОРИ
Мария Грация РОНКАРОЛО (IT)
Мария Грация РОНКАРОЛО
Вероник ЛУ (FR)
Вероник ЛУ
Грегорио АВЕРСА (CA)
Грегорио АВЕРСА
Маргит ЙЕШКЕ (CH)
Маргит ЙЕШКЕ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en
Priority claimed from GB0414309A external-priority patent/GB0414309D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2006112598A publication Critical patent/RU2006112598A/ru
Application granted granted Critical
Publication of RU2386639C2 publication Critical patent/RU2386639C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2006112598/13A 2003-09-18 2004-09-17 Связывающие молекулы, обладающие терапевтической активностью RU2386639C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/666,332 US20050069538A1 (en) 2003-09-18 2003-09-18 Therapeutic binding molecules
US10/666,332 2003-09-18
GB0414309A GB0414309D0 (en) 2004-06-25 2004-06-25 Organic compounds
GB0414309.5 2004-06-25

Publications (2)

Publication Number Publication Date
RU2006112598A RU2006112598A (ru) 2007-10-27
RU2386639C2 true RU2386639C2 (ru) 2010-04-20

Family

ID=34315457

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006112598/13A RU2386639C2 (ru) 2003-09-18 2004-09-17 Связывающие молекулы, обладающие терапевтической активностью

Country Status (28)

Country Link
EP (1) EP1664122B1 (https=)
JP (1) JP4762142B2 (https=)
KR (1) KR20060079232A (https=)
AR (2) AR045765A1 (https=)
AT (1) ATE461219T1 (https=)
AU (1) AU2004272289B2 (https=)
BR (1) BRPI0414515A (https=)
CA (1) CA2537217A1 (https=)
CY (1) CY1110033T1 (https=)
DE (1) DE602004026081D1 (https=)
DK (1) DK1664122T3 (https=)
EC (1) ECSP066432A (https=)
ES (1) ES2341341T3 (https=)
HR (1) HRP20100334T1 (https=)
IL (1) IL173820A0 (https=)
IS (1) IS8397A (https=)
MA (1) MA28041A1 (https=)
MY (1) MY143963A (https=)
NO (1) NO20061681L (https=)
NZ (1) NZ545605A (https=)
PE (1) PE20060019A1 (https=)
PL (1) PL1664122T3 (https=)
PT (1) PT1664122E (https=)
RU (1) RU2386639C2 (https=)
SI (1) SI1664122T1 (https=)
TN (1) TNSN06087A1 (https=)
TW (1) TW200521231A (https=)
WO (1) WO2005026210A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TWI579722B (zh) * 2015-02-17 2017-04-21 陳沛隆 藥物不良反應風險評估方法及其裝置
HK1249534A1 (zh) 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
WO2022020583A1 (en) * 2020-07-24 2022-01-27 The Board Of Trustees Of The Leland Standford Junior University Compositions and methods for modulation of sirpalpha-mediated signaling
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94038045A (ru) * 1991-07-25 1995-11-27 Айдек Фармасьютикалс Корпорейшн Антитела, нуклеиновые кислоты, способы выделения гена, способ получения антитела, способы лечения, фармацевтическая композиция

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170256C2 (ru) * 1991-07-25 2001-07-10 Айдек Фармасьютикалс Корпорейшн Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94038045A (ru) * 1991-07-25 1995-11-27 Айдек Фармасьютикалс Корпорейшн Антитела, нуклеиновые кислоты, способы выделения гена, способ получения антитела, способы лечения, фармацевтическая композиция

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Friend et. al., "Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection", Transplantation, vol.68 (11), стр.1632-1637, 1999. *

Also Published As

Publication number Publication date
SI1664122T1 (sl) 2010-07-30
AU2004272289B2 (en) 2008-09-18
ES2341341T3 (es) 2010-06-18
KR20060079232A (ko) 2006-07-05
AR045765A1 (es) 2005-11-09
NO20061681L (no) 2006-06-13
HK1091844A1 (en) 2007-01-26
EP1664122A2 (en) 2006-06-07
IL173820A0 (en) 2006-07-05
AR079458A2 (es) 2012-01-25
DE602004026081D1 (de) 2010-04-29
HRP20100334T1 (hr) 2010-07-31
WO2005026210A2 (en) 2005-03-24
JP4762142B2 (ja) 2011-08-31
ECSP066432A (es) 2006-09-18
JP2007529196A (ja) 2007-10-25
EP1664122B1 (en) 2010-03-17
RU2006112598A (ru) 2007-10-27
PT1664122E (pt) 2010-05-10
TNSN06087A1 (en) 2007-10-03
CY1110033T1 (el) 2015-01-14
CA2537217A1 (en) 2005-03-24
PE20060019A1 (es) 2006-02-27
MY143963A (en) 2011-07-29
NZ545605A (en) 2009-03-31
PL1664122T3 (pl) 2010-08-31
BRPI0414515A (pt) 2006-11-07
WO2005026210A3 (en) 2005-07-14
TW200521231A (en) 2005-07-01
DK1664122T3 (da) 2010-06-28
IS8397A (is) 2006-04-03
ATE461219T1 (de) 2010-04-15
AU2004272289A1 (en) 2005-03-24
MA28041A1 (fr) 2006-07-03

Similar Documents

Publication Publication Date Title
RU2386639C2 (ru) Связывающие молекулы, обладающие терапевтической активностью
RU2207878C2 (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
Whiteaker et al. Discovery, synthesis, and structure activity of a highly selective α7 nicotinic acetylcholine receptor antagonist
US20250205319A1 (en) Systems, compositions, and methods for transplantation
US5639455A (en) Immunosuppressant
RU2377254C2 (ru) Мутанты анти-cd40 антитела
JP2024038040A5 (https=)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
RU2003126168A (ru) Терапевтические связывающие молекулы
Luger et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
EP2066349A4 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
RU2000109255A (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
WO2003048327A3 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
BRPI0716088A8 (pt) anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para produzir um anticorpo, hibridoma, métodos para aliviar um ou mais sintomas de doença, e para diminuir ou inibir a ligação de hlight a hvem, ltbr, dcr3 ou qualquer combinação dos mesmos, e para diminuir ou inibir a secreção de ccl20, il-8, rantes ou qualquer combinação dos mesmos, e, kit
CN111164105B (zh) 抗pacap抗体
US20050276806A1 (en) Treatment of autism
JP2011032188A (ja) 融合蛋白質
Wu et al. Tick cysteine protease inhibitors suppress immune responses in mannan-induced psoriasis-like inflammation
Pendergraft III et al. Autoantigen complementarity and its contributions to hallmarks of autoimmune disease
US20030059428A1 (en) Treatment of autoimmune diseases
US20030223995A1 (en) Treatment of pemphigus vulgaris
EP1838731B1 (en) Use of ferrous ions for increasing the immunoreactivity of immunoglobulin preparations
SELA Therapeutic Vaccines Against Cancer and Autoimmune Diseases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120918